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Summary
Paraneoplastic cerebellar degeneration (PCD) is a
heterogeneous group of disorders characterized by sub-
acute cerebellar ataxia, speci®c tumour types and
(often) associated antineuronal antibodies. Nine speci®c
antineuronal antibodies are associated with PCD. We
examined the relative frequency of the antineuronal
antibodies associated with PCD and compared the
neurological symptoms and signs, associated tumours,
disability and survival between groups of PCD with
different antibodies. Also, we attempted to identify
patient-, tumour- and treatment-related characteristics
associated with functional outcome and survival. In a
12-year period, we examined >5000 samples for the
presence of antineuronal antibodies. A total of 137
patients were identi®ed with a paraneoplastic neuro-
logical syndrome and high titre (>400) antineuronal
antibodies. Fifty (36%) of these patients had antibody-
associated PCD, including 19 anti-Yo, 16 anti-Hu, seven
anti-Tr, six anti-Ri and two anti-mGluR1. Because of
the low number, the anti-mGluR1 patients were
excluded from the statistical analysis. While 100% of
patients with anti-Yo, anti-Tr and anti-mGluR1 anti-
bodies suffered PCD, 86% of anti-Ri and only 18% of
anti-Hu patients had PCD. All patients presented with
subacute cerebellar ataxia progressive over weeks to
months and stabilized within 6 months. The majority of
patients in all antibody groups had both truncal and
appendicular ataxia. The frequency of nystagmus and
dysarthria was lower in anti-Ri patients (33 and 0%).
Later in the course of the disease, involvement of non-
cerebellar structures occurred most frequently in anti-
Hu patients (94%). In 42 patients (84%), a tumour was
detected. The most commonly associated tumours were
gynaecological and breast cancer (anti-Yo and anti-Ri),
lung cancer (anti-Hu) and Hodgkin's lymphoma (anti-
Tr and anti-mGluR1). In one anti-Hu patient, a suspect
lung lesion on CT scan disappeared while the PCD
evolved. Seven patients improved by at least 1 point on
the Rankin scale, while 16 remained stable and 27
deteriorated. All seven patients that improved received
antitumour treatment for their underlying cancer,
resulting in complete remission. The functional outcome
was best in the anti-Ri patients, with three out of six
improving neurologically and ®ve were able to walk at
the time of last follow-up or death. Only four out of 19
anti-Yo and four out of 16 anti-Hu patients remained
ambulatory. Also, survival from time of diagnosis was
signi®cantly worse in the anti-Yo (median 13 months)
and anti-Hu (median 7 months) patients compared with
anti-Tr (median >113 months) and anti-Ri (median >69
months). Patients receiving antitumour treatment (with
or without immunosuppressive therapy) lived signi®-
cantly longer [hazard ratio (HR) 0.3; 95% con®dence
interval (CI) 0.1±0.6; P = 0.004]. Patients >60 years old
lived somewhat shorter from time of diagnosis, although
statistically not signi®cant (HR 2.9; CI 1.0±8.5; P = 0.06).
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Introduction
Subacute cerebellar ataxia in a patient with a known cancer is
often due to metastatic invasion or other complications of the
cancer, such as infection, coagulopathy, metabolic and
nutritional de®cits or side effects of treatment (Henson and
Urich, 1982). When tumour- and treatment-related causes
have been excluded, the patient is considered to suffer from
paraneoplastic cerebellar degeneration (PCD). In adult
patients who are not known to have a malignancy, subacute
cerebellar ataxia may cause a diagnostic challenge, as PCD
can precede the presentation of a neoplasm by several months
to years (Posner, 1995). In these patients, the detection of
high titre antineuronal autoantibodies directed against
onconeural antigens establishes the diagnosis of PCD and
directs the search towards an underlying neoplasm (Table 1).
Brouwer ®rst described PCD in 1919 (Brouwer, 1919), but
the association of cerebellar ataxia and cancer was not
recognized until 1938 (Brouwer and Biemond, 1938).
Ovarian, lung and breast cancer and Hodgkin's lymphoma
are the neoplasms most commonly associated with PCD
(Henson and Urich, 1982). The pathology of PCD is
characterized by severe loss of cerebellar Purkinje cells and
the presence of in¯ammatory in®ltrates in affected areas of
the nervous system (Henson and Urich, 1982). Trotter et al.
(1976) ®rst described autoantibodies reactive with cerebellar
Purkinje cells in the serum of a patient with Hodgkin's
lymphoma and PCD. Since then, the search for paraneoplastic
antineuronal antibodies (Abs) associated with PCD has
resulted in the identi®cation of many paraneoplastic Abs
and the subsequent cloning of their onconeural target antigens
(Table 1). PCD represents a heterogeneous group of related
disorders that differ in their clinical features, prognosis,
associated neoplasms and type of paraneoplastic Abs (Posner,
1995).
We reviewed 137 subjects with a de®nite, Ab-associated,
paraneoplastic neurological syndrome (PNS) in order to
determine the relative frequency of PCD. We subsequently
studied the 50 identi®ed PCD patients to compare neuro-
logical signs and symptoms, associated tumours, disability
and survival between groups of patients with different Abs. In
addition, we attempt to identify patient-, tumour- and
treatment-related characteristics associated with neurological
disability and survival.
Methods
Immunological studies
In a 12-year period (1989±2001), we examined serum and
CSF samples from ~5000 patients. Physicians who suspected
that their patients suffered from PNS had submitted the
patient samples to our laboratory for determination of
paraneoplastic antineuronal Abs. During the entire study
period, all samples were screened on rat frozen cerebellar
sections using indirect immuno¯uorescence (Moll et al.,
1993). All positive sera were con®rmed by western blotting,
using rat cerebellar extract (Moll et al., 1993; Honnorat et al.,
1998) and puri®ed recombinant HuD, CDR62, amphiphysin
and NOVA-1 antigens (Fathallah-Shaykh et al., 1991;
Buckanovich et al., 1993; De Camilli et al., 1993; Manley
et al., 1995). Anti-Tr was diagnosed by strict immunohisto-
chemical criteria when Purkinje cell cytoplasmic staining was
combined with a characteristic punctuated staining of
Purkinje cell dendrites (Graus et al., 1998). Anti-mGluR1
was con®rmed by reactivity with mGluR1-expressing
Chinese hamster ovary (CHO) cells (Sillevis Smitt et al.,
2000). Titration was performed by indirect immuno¯uores-
cence, and titres were reported as the reciprocal of the highest
dilution yielding clearly positive staining. Only sera with
speci®c staining patterns at titres >400 combined with
reactivity with puri®ed onconeural fusion protein were
considered in this study. Patients were considered affected
by PCD when they presented with cerebellar ataxia not
attributable to metastases, infection, metabolic, hereditary,
toxic or iatrogenic causes combined with the detection of high
titre (>400) antineuronal Ab.
Subjects
We have identi®ed a total of 137 patients with high titre
antineuronal Abs. Fifty (36%) of these patients had PCD,
including 19 anti-Yo, 16 anti-Hu, seven anti-Tr, six anti-Ri
and two anti-mGluR1 (Table 2). While 100% of patients with
anti-Yo, anti-Tr or anti-mGluR1 Abs suffered PCD, 86% of
anti-Ri and only 18% of anti-Hu patients had PCD. None of
the patients with anti-amphiphysin or anti-CV2 Abs in our
series presented with PCD. Fourteen of the 50 PCD patients
were seen at the Erasmus University Medical Centre
Rotterdam, and the hospital charts of these patients were
reviewed. Samples from the other 36 patients had been
submitted by physicians, mostly from The Netherlands and
Belgium, and clinical information was obtained from review
of the case records sent to us by their outside medical
specialists. Follow-up information was obtained from the
patients' general practitioners.
Patient information was reviewed for neurological signs
and symptoms at presentation and after stabilization of the
syndrome. CNS dysfunction was classi®ed as cerebellar
degeneration, limbic encephalitis, brainstem encephalitis or
myelitis. Cerebellar signs and symptoms were classi®ed
further as ataxia (predominantly truncal, appendicular or
both), nystagmus and dysarthria. Signs and symptoms of
peripheral nervous system dysfunction were classi®ed as
peripheral neuropathy (sensory, mixed somatic, autonomic or
motor neuronopathy), focal neuropathy or radiculopathy.
Fifty patients with predominantly cerebellar symptoms and
signs at presentation were identi®ed (Table 2).
The neurological disability was scored using a modi®ed
Rankin scale (RS) (Graus et al., 1992; Keime-Guibert et al.,
1999) at the time of diagnosis (®rst positive antineuronal Ab
result), before onset of treatment and at last follow-up. On the
modi®ed RS, a score of 0 represents an asymptomatic patient;
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1, symptoms that do not interfere with lifestyle; 2, symptoms
that lead to some restriction of lifestyle but do not prevent
totally independent existence; 3, symptoms that signi®cantly
interfere with lifestyle or prevent totally independent exist-
ence; 4, symptoms that clearly prevent independent existence,
although the patient does not need constant attention; and 5,
severe disability is present with total dependence requiring
constant attention. A patient was considered neurologically
improved or deteriorated if there was a change of at least 1
point in the RS score measured at the time of diagnosis
(positive Ab test) or onset of the treatment compared with
the RS score at the time of stabilization of the symptoms
(Keime-Guibert et al., 2000).
Statistical analysis
Due to the low number, the two patients with anti-mGluR1-
associated PCD were excluded from the statistical analysis,
leaving 48 patients. End points included overall survival (OS)
from date of diagnosis (anti-neuronal Ab) and functional
outcome at stabilization. OS was calculated until the date of
death from any cause. Patients still alive at the date of last
contact were then censored. OS was estimated by the Kaplan±
Meier method, and Kaplan±Meier curves of the four anti-
neuronal Ab groups were compared using the log-rank test.
The following variables were included in the analysis of
prognostic factors: type of anti-neuronal Ab, age at diagnosis
(<59 versus >60 years), presence of tumour, RS score at
diagnosis (0±3 versus 4±5) and treatment (no treatment versus
immunotherapy only versus antitumour treatment with or
without immunotherapy).
Patient characteristics of the four antineural Ab groups
were compared using Fisher's exact test in the case of discrete
variables or the Kruskal±Wallis test in the case of continuous
variables.
Univariate Cox regression analysis was used to detect
differences in OS between subgroups. Univariate logistic
regression was used to test for a difference in functional
outcome between subgroups.
We used Spearman's rank correlation to test whether there
was an association between RS score at diagnosis and the
time between onset of neurological symptoms and the date of
diagnosis.
All P values are two-sided, and a signi®cance level a = 0.05
was used. All statistical analyses were performed using Stata
software (StataCorp. 2001, Stata Statistical Software: Release
7.0, Stata Corporation, College Station, TX) and GraphPad
Prism version 3.0 software (GraphPad Software, Inc., San
Diego, CA, 1999).
Results
Patient characteristics
Patient characteristics are summarized in Table 3. All patients
presented with a subacute cerebellar syndrome that evolved
over weeks to months and stabilized within 6 months. The
patients in the anti-Tr group tended to be younger than those
in the other groups, re¯ecting the different age distribution of
the associated tumours, in particular Hodgkin's disease.
However, this was not statistically signi®cant (P = 0.4). The
median interval between the onset of symptoms and de®nite
diagnosis of PCD (de®ned by detection of speci®c Ab) varied
slightly between 3.5 months (anti-Yo) and 6.0 months (anti-
Hu) (P = 0.9). At the time of diagnosis of PCD, the majority
of patients in all Ab groups suffered both truncal and
appendicular ataxia. The frequency of nystagmus and
dysarthria was lower in anti-Ri patients (33 and 0%) than in
the anti-Yo (68 and 84%), anti-Hu (69 and 50%) and anti-Tr
(86 and 86%) patients. In all patients, the predominant
neurological syndrome at the time of PCD diagnosis was
cerebellar ataxia. Many developed additional, non-cerebellar
symptoms or signs (Table 3). Involvement of non-cerebellar
structures occurred most frequently in anti-Hu patients,
indicating that PCD associated with anti-Hu Abs represents
a more diffuse paraneoplastic encephalomyelitis. Despite
these differences, the RS score at the time of diagnosis did not
differ signi®cantly between the patient groups (P = 0.6).
Associated tumours
The associated tumours in the ®ve patient groups are
summarized in Table 4. A tumour was diagnosed in 42 of
Table 2 Main clinical syndromes at presentation and high titre (>400) paraneoplastic antineuronal autoantibodies
detected over a 12-year period (1989±2001)
Antibody n PCD (%) PSN PLE PEM POM SPS
Anti-Hu 90 16 (18) 46 14 13 1 ±
Anti-Yo 19 19 (100) ± ± ± ± ±
Anti-Tr 7 7 (100) ± ± ± ± ±
Anti-Ri 7 6 (86) ± ± ± 1 ±
Anti-amphiphysin 7 ± 4 1 1 ± 1
Anti-CV2 5 ± 3 1 1 ± ±
Anti-mGluR1 2 2 (100) ± ± ± ± ±
Total 137 50 (37) 53 16 15 2 1
PSN = paraneoplastic sensory neuropathy; PLE = paraneoplastic limbic encephalitis; PEM = paraneoplastic encephalomyelitis;
POM = paraneoplastic opsoclonus/myoclonus; SPS = stiff person syndrome.
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50 PCD patients (84%). In 26 (62%) of these tumour patients,
the PCD preceded the diagnosis of the tumour. In 10 of the 15
anti-Yo patients (67%) with a tumour, the PCD presented in
patients already known to have a cancer. Nine of these
patients had reached complete remission (CR) following
initial antitumor treatment. In ®ve, the PCD was shortly
followed by tumour recurrence; in three, the tumour recurred
prior to PCD; and two remained free of recurrent tumour. One
patient died 3 months after onset of PCD, 2.5 years after
reaching CR for ovarian cancer. At autopsy, no recurrent
tumour was found and neuropathological examination dem-
onstrated complete loss of Purkinje cells. The second patient
developed PCD 22 months after reaching CR for ovarian
cancer. At last follow-up, 2 years after onset of PCD, regular
gynaecological examinations had not yet revealed a recur-
rence.
In eight patients, no tumour was demonstrated. Four anti-
Yo patients had no detected tumour. Two of these patients
were still alive at the time of last follow-up, 44 and 58 months
from onset of symptoms. Of the two deceased patients, one
had mildly elevated CA125 and weight loss. She probably
had an underlying ovarian cancer that could not be demon-
strated, and died 32 months after onset of symptoms. The
second deceased patient was in a poor condition; the family
declined an extensive work-up and she died 9 months after
onset of PCD. Due to the limited work-up, an underlying
malignancy has not been excluded.
Of the two anti-Hu patients without demonstrable tumour,
one had a suspect adrenal lesion possibly representing an
adrenal small cell lung carcinoma (SCLC) metastasis. This
diagnosis was not pursued further because of the patient's
poor clinical condition, and she died 10 months after the
diagnosis of PCD in a nursing home. The other patient is a 58-
year-old man with a long history of cigarette smoking who
presented with a mainly appendicular ataxia. He subsequently
developed a pancerebellar syndrome and brainstem signs.
Anti-Hu Abs were tested positive 18 months after onset of
symptoms. The patient remained ambulatory but could not
Table 3 Clinical characteristics of 48 PCD patients
Anti-Yo Anti-Hu Anti-Tr Anti-Ri Anti-mGluR1
No. of patients 19 16 7 6 2
F/M 19/0 4/12 1/6 5/1 2/±
Age at diagnosis (median, range) (years) 64 (37±79) 67 (51±79) 54 (29±73) 65 (52±76) 19, 50
Additional neurological symptoms:
Peripheral neuropathy ± 8 ± ± ±
Limbic encephalitis ± 4 1 1 1
Brainstem encephalitis 6 10 ± 3 ±
Opsoclonus/myoclonus ± 1 ± 4 ±
Myelitis ± 1 ± 1 ±
Isolated PCD 13 1 6 2 1
Median delay between symptoms and diagnosis (range) 3.5 (0.3±52.8) 6.0 (0.9±18.4) 4.8 (1.2±13.0) 5.2 (0.8±13.3) 0.5 (0.5±12)
No. of patients with tumour 15 14 6 5 2
PCD before tumour diagnosis 5 13 6 2 ±
Median interval PCD to tumour diagnosis (range) 3.5 (0.3±52.8) 6.0 (0.9±18.4) 4.8 (1.2±13.0) 5.2 (0.8±13.3) ±
Median survival (months) 13 7 >113 >69 24
Cause of death*
Neurological 8 6 1 1 ±
Oncological 4 2 ± ± ±
Unknown/unrelated ± 2 ± ± 1
*Death was scored as oncological when the patient died from tumour progression and as neurological when the paraneoplastic process
contributed directly to death (e.g. in brainstem encephalitis) or when the neurological disability was judged to be a major contributing
factor to death (e.g. pneumonia in a bedridden patient).
Table 4 Associated tumours in 50 PCD patients
Antibody n Lung Gynaecological Breast Hodgkin's Other No tumour
Anti-Yo 19 ± 9 3 ± 3 4
Anti-Hu 16 14 ± ± ± ± 2
Anti-Tr 7 ± ± ± 6 ± 1
Anti-Ri 6 ± 1 3 ± 1 1
Anti-mGluR1 2 ± ± ± 2 ± ±
Total 50 14 10 6 8 4 8
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live independently. A CT scan demonstrated a suspect lesion
in the left upper lobe. The lesion disappeared spontaneously
and, at the time of last follow-up, 68 months after onset of the
ataxia, the patient was alive without signs of cancer.
In one anti-Tr and one anti-Ri patient, no tumour was
found. The anti-Tr patient died 10 months after PCD onset. At
autopsy, no tumour was detected. The anti-Ri patient has
remained free of cancer during 4.5 years of follow-up.
Neurological outcome
The neurological outcome is presented in Table 5. In general,
at the time of neurological diagnosis, 63% of patients were
ambulatory (RS score <3). When PCD had reached its plateau
phase, only 34% were still able to walk. The functional
outcome was signi®cantly different between the four patient
groups (P = 0.04). Outcome was worst in the anti-Yo patients
(79% bedridden) followed by anti-Hu (75%), anti-Tr (57%)
and anti-mGluR1 (50%) patients. The prognosis in the anti-Ri
patients was much better, and 83% retained their ability to
walk. Using logistic regression, age >60 years [odds ratio
(OR) 5.4; 95% con®dence interval (CI) 1.4±21.2; P = 0.02]
and a higher RS score at diagnosis (OR 3.8; 95% CI 0.9±16.1;
P = 0.07) predicted worse functional outcome (RS 4±5).
Neither immunotherapy (OR 0.4; 95% CI 0.1±2.8; P = 0.4)
nor antitumour treatment (OR 0.3; 95% CI 0.1±2.0; P = 0.3)
signi®cantly affected functional outcome (Table 6). Seven
patients (14%) improved neurologically from the time of
diagnosis or start of treatment: three anti-Ri patients and one
each with anti-Yo, anti-Hu, anti-Tr and anti-mGluR1 Abs
(Table 7). Remarkably, all patients who improved neurolo-
gically received antitumour treatment, and CR was achieved
in all. Patient 2 (Table 7) developed PCD shortly after
diagnosis of a lymph node metastasis in the groin, probably
from an ovarian cancer. At presentation, her RS score was 3
(ambulatory) but she deteriorated despite intravenous im-
munoglobulin G (IVIg) treatment and became bedridden (RS
score = 4) prior to transfer to our hospital. After obtaining
informed consent, she was treated with four cycles of
rituximab (375 mg/m2). After the ®rst cycle, she regained
her ability to walk (RS score = 3) and remained stable for >1
year. Rituximab (Roche Ltd, Basel, Switzerland) is a
chimeric mouse±human anti-CD20 monoclonal Ab effect-
ively used in the treatment of B-cell lymphomas (Maloney
et al., 1994, 1997). Rituximab has also been effective in a
variety of Ab-associated autoimmune disorders (Arzoo et al.,
2002). In patient 2, the rituximab treatment eliminated
circulating CD19+ B cells but did not result in lower anti-
Yo titres in serum (Table 7) or CSF. In the patients with anti-
Tr and anti-mGluR1, the Abs had disappeared from the serum
Table 5 Neurological outcome in 50 PCD patients
Functional status Anti-Yo Anti-Hu Anti-Tr Anti-Ri Anti-mGluR1 All patients
No. of patients 19 16 7 6 2 50
At diagnosis
RS score <3 11 9 6 4 1 31
RS score >4 8 7 1 2 1 19
Evolution RS score
Improved (>1 point) 1 1 1 3 1 7
Stable 4 7 3 1 1 16
Deterioration (>1 point) 14 8 3 2 ± 27
At plateau
RS score <3 4 4 3 5 1 17
RS score >4 15 12 4 1 1 33
Table 6 Neurological outcome by treatment in 50 PCD patients
Treatment/outcome Anti-Yo Anti-Hu Anti-Tr Anti-Ri Ant-mGluR1 All patients
No. of patients 19 16 7 6 2 50
Patients with tumour 15 14 6 5 2 42
Antitumour treatment 5 1 3 1 ± 10
Improved/stable ± 1 2 ± ± 3
Immunosuppression 4 5 ± 3 2 14
Improved/stable 2 2 ± 2 1 7
Both treatments 6 2 3 2 ± 13
Improved/stable 2 2 2 2 ± 8
No treatment 4 7 1 ± ± 12
Improved/stable 2 4 ± ± ± 6
Patients are considered improved or stable when the RS score from time of diagnosis of PCD did not deteriorate.
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at the time of clinical improvement (Table 7). In one of the
anti-Ri patients, clinical improvement was paralleled by a
decline in Ab titre, while high titres remained in the second
anti-Ri patient despite neurological improvement. No follow-
up serum was available from the third anti-Ri and the anti-Hu
patients who had improved clinically.
Survival
The median survival of anti-Hu patients from time of
diagnosis was 7 months, compared with 13 months in anti-
Yo patients (Fig. 1). This difference in survival was
statistically not signi®cant [hazard ratio (HR) 1.7; 95% CI
0.7±3.9; P = 0.2]. Anti-Tr patients (median >113 months)
lived signi®cantly longer from time of ®rst symptoms than
anti-Yo (HR 0.12; 95% CI 0.02±0.97; P = 0.05) and anti-Hu
patients (HR 0.13; 95% CI 0.02±1.00; P = 0.05). Anti-Ri
patients (median >69 months) also lived longer than anti-Yo
and anti-Hu patients, but the differences were not signi®cant.
In patients >60 years, there was a non-signi®cant trend
towards shorter survival from time of diagnosis (HR 2.9; 95%
CI 1.0±8.5; P = 0.06). Patients receiving antitumour treatment
(with or without immunosuppressive therapy) lived signi®-
cantly longer (HR 0.3; 95% CI 0.1±0.6; P = 0.004). However,
after adjustment for Ab group, there was no statistically
signi®cant treatment effect.
Discussion
We found that 36% of 137 patients with a de®nite PNS
presented with subacute cerebellar ataxia, indicating that
PCD is a common presentation of Ab-associated PNS. While
anti-Hu was the most frequent paraneoplastic Ab detected in
our study (66% of 137 patients), only 18% presented with
PCD. In contrast, 100% of anti-Yo, anti-Tr and anti-mGluR1,
and 86% of anti-Ri patients presented with PCD. In PCD
patients, anti-Yo (38%) was detected most frequently,
followed by anti-Hu (32%), anti-Tr (14%) and anti-Ri
(12%) Abs. During the course of the disease, additional
Table 7 Characteristics of seven PCD patients with improvement of functional status by at least 1 point on the modi®ed
Rankin scale
No. Antibody Age Tumour Antitumour treatment Immunosuppression RSD RSE STD STE
1 Anti-Hu 66 SCLC CR None 4 1 >1600 NA
2 Anti-Yo 47 Adenocarcinoma CR IVIg, rituximab 3* 3 6400 12 800
3 Anti-Tr 31 Hodgkin CR None 3 0 1600 Neg
4 Anti-Ri 58 Breast cancer CR PE, steroids, azathioprine 3 2 25 600 800
5 Anti-Ri 56 Tuba cancer CR Steroids 4 1 12 800 102 400
6 Anti-Ri 53 Breast cancer CR IVIg, steroids 4 2 3200 NA
7 Anti-mGluR1 19 Hodgkin CR IVIg, steroids, PE 3 0 3200 Neg
RSD = RS score at diagnosis; RSE = RS score at last follow-up; STD = serum antibody titre at diagnosis (IgG); STE = serum antibody
titre after clinical improvement (IgG); NA = not available; Neg = negative; PE = plasma exchange. *This patient was diagnosed with PCD
while still ambulatory (RSD = 3). She subsequently became bedridden (RS score = 4) despite treatment with IVIg. Following treatment
with rituximab, she regained her ability to walk (RS score = 3) for > 1 year (see Results).
Fig. 1 Kaplan±Meier survival curves of 48 PCD patients with associated anti-Yo, anti-Hu, anti-Tr or anti-Ri antibodies.
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non-cerebellar symptoms occurred most frequently in the
anti-Hu patients (94%), indicating that PCD associated with
anti-Hu Abs is part of a more widespread paraneoplastic
encephalomyelitis/sensory neuronopathy (PEM/SN) (Dalmau
et al., 1992; Graus et al., 2001; Sillevis Smitt et al., 2002).
The median age of the anti-Hu, anti-Yo and anti-Ri patients
was 64±67 years and of the anti-Tr patients was 54 years. The
latter median age is remarkable because all anti-Tr patients
had associated Hodgkin's lymphoma. The age distribution of
Hodgkin's lymphoma is bimodal, with an early peak in young
adults and a second peak after age 50 (Gutensohn and Cole,
1980). Most anti-Tr and one of the anti-mGluR1 PCD patients
belong to the second age peak, which may re¯ect a different
mechanism in the pathogenesis of the Hodgkin's lymphoma
between the two age groups.
Survival varied signi®cantly between PCD patients with
different Abs. The median survival from time of diagnosis in
the anti-Hu patients was 7 and in anti-Yo patients 13 months,
con®rming the grim prognosis (Rojas et al., 2000; Graus et al.,
2001; Sillevis Smitt et al., 2002). In contrast, the median
survival in the anti-Tr (>117 months) and anti-Ri (>69
months) was not reached. Other factors predicting longer
survival were administration of antitumour treatment and
younger age.
In our study, 67% of the deceased anti-Yo patients died of a
neurological cause, con®rming two earlier reports (Hammack
et al., 1990; Peterson et al., 1992). In contrast, Rojas et al.
(2000) described death by a neurological cause in only 29%
of anti-Yo patients, the majority dying from tumour progres-
sion. This difference is not explained by the associated
malignancies. The most common associated tumours in anti-
Yo patients were gynaecological (Hammack et al., 1990;
Peterson et al., 1992; Rojas et al., 2000), in anti-Hu patients
lung cancer (Dalmau et al., 1992; Graus et al., 2001; Sillevis
Smitt et al., 2002), in anti-Tr and anti-mGluR1 patients
exclusively Hodgkin's lymphoma (Graus et al., 1997), and in
anti-Ri patients breast cancer (Luque et al., 1991). No tumour
was detected in eight patients, while in one anti-Hu patient a
radiologically suspect lung lesion disappeared spontaneously
during the course of PCD. Remissions of radiologically
suspect lung lesions and histologically con®rmed SCLC
during anti-Hu-associated PEM/SN have been reported
previously (Darnell and DeAngelis, 1993; Zaheer et al.,
1993) and support an important role for HuD-speci®c
cytotoxic T lymphocytes (Benyahia et al., 1999; Plonquet
et al., 2002).
In accordance with previous studies, 75% of anti-Hu
patients became chair bound (Graus et al., 2001; Sillevis
Smitt et al., 2002). Although symptoms were limited to the
cerebellum in most, only 21% of the anti-Yo patients
remained ambulatory, con®rming previous reports of the
grim neurological prognosis (Hammack et al., 1990; Peterson
et al., 1992; Rojas et al., 2000). Neurological disability in
anti-Tr and anti-mGluR1 was less severe, and 43 and 50%
remained ambulatory, respectively. Anti-Ri PCD patients had
the best neurological prognosis; 83% remained ambulatory
and three out of six patients improved neurologically,
con®rming previous case reports (Dropcho et al., 1993;
Jongen et al., 1998).
We studied factors which were involved in the neuro-
logical disability. We found that age >60 years and a higher
RS score at diagnosis predicted worse functional outcome,
while neither immunosuppression nor antitumour treatment
had a signi®cant effect. Larger studies have demonstrated
better neurological outcome in patients receiving antitumour
treatment for anti-Hu associated PEM/SN (Graus et al.,
2001), while no such effect was demonstrated for anti-Yo-
related PCD (Rojas et al., 2000). However, of the seven
patients (14%) who improved neurologically, all had reached
a CR of the tumour following antitumour treatment, and four
had been treated additionally with some form of immu-
notherapy. One patient with anti-Yo-associated PCD re-
gained her ability to walk following rituximab (anti-CD20)
treatment. CD20 is a transmembrane surface antigen
expressed only by B-cell precursors and mature B cells, and
appears to play an important functional role in B-cell
activation, proliferation and differentiation (Tedder and
Engel, 1994). Rituximab is very effective in the treatment
of B-cell lymphomas (Maloney et al., 1994, 1997) and it is
used increasingly in the treatment of Ab-mediated auto-
immune disorders including paraneoplastic pemphigus
(Heizmann et al., 2001), myasthenia gravis (Zaja et al.,
2000) and polyneuropathy associated with IgM Abs (Levine
and Pestronk, 1999). Rituximab treatment results in long-
lasting peripheral blood B-cell depletion, and we hypothe-
sized that administration of rituximab would result in
elimination of pre-B cells, preventing formation of new Ab-
secreting cells and reducing anti-Yo titres not only in serum
but also in CSF. Despite complete depletion of circulating
CD19+ B cells in our patient, her CSF and serum anti-Yo IgG
titres remained high. Slight neurological ¯uctuations are
common in anti-Yo-associated PCD, but a signi®cant
improvement rarely if ever occurs in this aggressive disorder
(Peterson et al., 1992; Posner, 1995; Rojas et al., 2000),
suggesting some role for rituximab in the neurological
improvement in our patient. Although we do not fully
understand the mechanism, rituximab treatment currently is
under further evaluation. In three patients, the neurological
improvement was paralleled by a decrease in Ab titre (one
each with anti-Ri, anti-Tr and anti-mGluR1 Abs). In the anti-
mGluR1 patient, the clinical improvement may have resulted
directly from the disappearance of anti-mGluR1 from the
serum because these autoantibodies have been shown to block
the mGluR1 receptor in vivo (Sillevis Smitt et al., 2000). A
pathogenic role for anti-Yo and anti-Hu Abs could never be
proven in animal models (Graus et al., 1991; Sillevis Smitt
et al., 1995), and demonstration of antigen-speci®c cytotoxic
T lymphocytes in blood, CSF and target tissue (Benyahia
et al., 1999; Albert et al., 2000; Plonquet et al., 2002) has
shifted attention to a pathogenic role for the cellular immune
response. Conventional immunosuppression is not effective
in anti-Hu- and anti-Yo-associated PCD, and new treatment
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modalities directed at a rapid destruction of the immune
attack on the nervous system are warranted. Aggressive
autoimmune disorders, including multiple sclerosis, are
increasingly treated with haematopoietic stem cell trans-
plantation following myelosuppressive conditioning (Burt
et al., 1998; Fassas et al., 2002). In selected patients with an
aggressive course of PCD, autologous haematopoietic stem
cell transplantation may be considered in a carefully
controlled protocol. In patients with a more indolent course
and in patients with anti-Ri Abs, antitumour treatment and a
trial of conventional immunotherapy is recommended.
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